3-乙酰氧基-2(1H)-吡啶酮 | 61296-14-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-乙酰氧基-2(1H)-吡啶酮
• 英文名称: 1,2-dihydro-2-oxo-3-pyridyl acetate
• 英文别名: 3-Acetoxy-2-pyridone；(2-oxo-1H-pyridin-3-yl) acetate
• CAS: 61296-14-8
• 化学式: C₇H₇NO₃
• mdl: MFCD00006014
• 分子量: 153.137
• InChiKey: AVXFMBRAPTYFOX-UHFFFAOYSA-N

物化性质

• 熔点：
  145-149 °C(lit.)
• 沸点：
  370.8±35.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)
• 稳定性/保质期：

  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37
• 危险类别码：
  R22,R36/37/38,R43
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  3-乙酰氧基-2(1H)-吡啶酮 在 ammonium sulfate 、 三氟甲磺酸三甲基硅酯 、 三乙胺 、 二异丙胺 、 六甲基二硅氮烷 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成 1-β-D-ribofuranosyl-3-hydroxy-2-pyridone
  参考文献：
  名称：

  Synthesis of 3-hydroxy-2- and -4-pyridone nucleosides as potential antitumor agents

  摘要：

  The ribo- and arabinofuranosyl nucleosides of antitumor active 2- and 4-pyridones 1a and 2a were prepared by direct condensation of the silylated bases with either 1-O-acetyl-2,3,5-tri-O-benzoyl-D-ribofuranose (4a) or 2,3,5-tri-O-benzyl-1-p-nitrobenzoyl-D-arabinofuranose (7) in the presence of trimethylsilyl triflate (Me3SiOTf). In the case of the arabinofuranosyl nucleosides, separation of the alpha and beta anomers was accomplished at the stage of O-benzyl-protected compounds (8b + 9b, and 10b + 11b) after chemical functionalization of the 3-hydroxy group of the pyridone aglycons with acetyl and benzyl groups, respectively. Deblocking of the protected ribo- and arabinofuranosyl nucleosides was performed by the standard methods. In vitro activity against P-388 cells in culture indicated that the 4-pyridone riboside 6d was the most active member of the series with a twofold lower ID50 than the parent pyridone 2a. However, this and all the other compounds tested in this series showed no activity against the in vivo model system of murine P-388 leukemia at doses ranging from 25 to 400 mg/kg qd 1-5.

  DOI：

  10.1021/jm00368a010

文献信息

• Synthesis and antihypertensive activity of 4-(1,2-dihydro-2-oxo-1-pyridyl)-2H-1-benzopyrans and related compounds, new potassium channel activators
  作者：Rolf Bergmann、Rolf Gericke

  DOI：10.1021/jm00164a005

  日期：1990.2

  other heterocycles such as 4-pyridone, pyrimidone, pyridazinone, pyrazinone, and 1,4-butanesultam, the activity is maintained. The removal of the 3-hydroxy function (----17a) does not significantly reduce the activity. The elimination of water from the chromanols leads to the formation of the chromenes, which are among the most potent antihypertensives known. The influence of diverse substituents, in

  描述了4-（1,2-二氢-2-氧代-1-吡啶基）-2H-1-苯并吡喃-3-醇的合成和降压活性。未取代的吡啶酮加合物铅化合物7e具有高活性，吡啶酮环上的取代基导致活性降低。为了获得最佳活性，必须在C-6位上强烈吸电子的取代基。当2-吡啶酮环被其他杂环如4-吡啶酮，嘧啶酮，哒嗪酮，吡嗪酮和1,4-丁烷磺胺取代时，活性得以维持。3-羟基官能团（---- 17a）的去除不会显着降低活性。从苯并二氢吡喃醇中除去水会导致苯并二氢吡喃酮的形成，这是已知最有效的降压药之一。各种取代基，尤其是杂环C-6取代基的影响，以4-（2-氧代-1-吡咯烷基）色满-3-醇系列进行了研究。铬醇在3-羟基处被短链酸酯化，保持其活性。色烯双键的环氧化也产生活性化合物。环氧化物22的重排产生3-酮化合物23和烯醇衍生物25。酮23a的还原产生顺式-苯并二氢吡喃醇7ab及其反式异构体7e。在自发性高血压大鼠中以1 mg / kg
• Substituted pyrimidinyloxy pyridine derivatives as herbicides
  申请人：FMC Corporation

  公开号：US11006631B2

  公开（公告）日：2021-05-18

  Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, wherein Q, Z, R2, R3 and m are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of a compound or a composition of the invention.

  公开了式 1 的化合物，包括其所有立体异构体、N-氧化物和盐、 其中 Q、Z、R2、R3 和 m 的定义如本说明书所述。 本发明还公开了含有式 1 化合物的组合物，以及控制不良植被的方法，包括将有效量的本发明化合物或组合物与不良植被或其环境接触。
• HWANG D. R.; DRISCOLL J. S., J. PHARM. SCI., 1979, 68, NO 7, 816-819
  作者：HWANG D. R.、 DRISCOLL J. S.

  DOI：——

  日期：——
• BERGMANN, ROLF;GERICKE, ROLF, J. MED. CHEM., 33,(1990) N, C. 492-504
  作者：BERGMANN, ROLF、GERICKE, ROLF

  DOI：——

  日期：——
• AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF
  申请人：Genoa Pharmaceuticals, Inc.

  公开号：EP2670242A1

  公开（公告）日：2013-12-11

表征谱图